ArticleFrontiers in pharmacology2024

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system.

Jiawei Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.